- SheMed, a UK-based women's HealthTech firm, raised €43 million in funding
- The firm intends to enhance its healthcare services, technology, and data strength
- The intention is to deliver more preventive and personalised healthcare options for women
SheMed, the London-based female-founded HealthTech firm, has raised €43 million to grow its health platform and promote preventive care among women.
The investment will be used to drive growth in SheMed's UK business, including the doubling of its medical and tech teams, clinical infrastructure enhancements, and the build-out of data-driven capabilities.
Co-founder and CEO Olivia Ferro pointed out that SheMed was formed to offer women customized healthcare, driven by her personal experience with a GLP-1 condition.
Co-founder and President Chloe Ferro mentioned the high demand for services that take individual health concerns and experiences into consideration.
Established in April 2024 by the Ferro sisters, SheMed has rapidly become a top provider of personalized women's healthcare, combining medical supervision, wellness tracking, and 24/7 support through its online platform.
The company has already seen more than 60,000 members in its first year and runs the UK's fastest-growing GLP-1 and weight-management scheme.
The investment is indicative of wider trends in UK and European HealthTech, and especially in preventive and women's healthcare, with other ventures including Numan and Hormona also drawing in substantial financing this year.
Funding will also be directed towards research and innovation that helps enhance patient experience and access to personalised treatment.
By the end of this month, SheMed is set to announce the findings of the first female-specific GLP-1 clinical trial, providing insights into the impact of these drugs on women's hormonal and metabolic responses and guiding future treatment strategies.
.jpg "IIM – A: Nurturing Business Leaders of Tomorrow")
